DOCSLIB.ORG

Review Memorandum

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k103161 B. Purpose for Submission: New device C. Measurand: Opiates, oxycodone and hydrocodone in hair D. Type of Test: Qualitative ELISA Immunoassay E. Applicant: Omega Laboratories, Inc. F. Proprietary and Established Names: Omega Laboratories Hair Drug Screening Assays for Opiates, Oxycodone and Hydrocodone G. Regulatory Information: Product Code Classification Regulation Section Panel DJG, Enzyme immunoassay Class II 862.3650 91-Toxicology Opiates H. Intended Use: 1. Intended use(s): See Indications for use below. 2. Indication(s) for use: 1 The Omega Laboratories Hair Drug Screening Assays are test systems that utilize ELISA assays for the qualitative detection of morphine and related opiates (calibrated with morphine) and oxycodone and hydrocodone (calibrated with oxycodone) at or above 300 pg/mg in head hair samples. The Omega Laboratories Hair Drug Screening Assay for Opiates, Oxycodone and Hydrocodone provide only preliminary analytical test results. A more specific alternate chemical method must be used in order to obtain a confirmed result. Gas Chromatograph– Mass Spectrometry operating in the selected ion monitoring (SIM) mode or GC/MS/MS in selected reaction mode (SRM) is the preferred method with deuterated internal standards. Other chemical confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are obtained. These tests are intended exclusively for in-house use only and are not intended for sale to anyone. Omega offers these tests as services to its clients. 3. Special conditions for use statement(s): The assay is for Over the Counter Use. 4. Special instrument requirements: The screening assay is for use with an automated microplate reader capable of measuring at 450 nm. For confirmation testing, the sponsor uses an Agilent GC/MS in selected ion monitoring (SIM) mode using deuterated internal standards. I. Device Description: The assay consists of the following: • Hair sample collection kit • Micro strip plates coated with either anti-morphine mouse monoclonal or anti- oxycodone rabbit polyclonal antibody, enzyme conjugate (horseradish peroxidase conjugated to morphine or oxycodone), substrate (containing tetramethylbenzidine), an enzyme diluent, and wash solution • In-house prepared calibrators and controls are used. These are prepared solutions of morphine and oxycodone added to negative hair matrix tubes. J. Substantial Equivalence Information: 1. Predicate device name(s): Quest Diagnostic HairCheck-DT (Opiates) American BioMedica Corporation, RapidOne–OXY Test (Oxycodone) 2 2. Predicate K number(s): k042725 k014101 3. Comparison with predicate: Item Proposed Device Quest Hair Drug Screening RapidOne – OXY Test k042725 K014101 Indications/ The Omega Laboratories Quest Diagnostics RapidOne-OXY Test is a Intended Use Hair Drug Screening HairCheck-DT (Opiates) is one-step, lateral flow Assays are test systems a test system that utilizes immunoassay for the that utilize ELISA assays the IDS One step ELISA detection of oxycodone in for the qualitative detection Opiates Kit for the urine. RapidOne-OXY of morphine and related qualitative detection of Test is intended for the opiates, oxycodone and opiates at concentrations at qualitative detection of hydrocodone at or above or above 300 pg/mg hair oxycodone inhuman urine 300 pg/mg in head hair for the purpose of at 100 ng/mL. RapidOne- samples. identifying chronic use of OXY Test is intended for heroine. This test system professional use. It is not The Omega Laboratories has not been evaluated for intended for over the Hair Drug Screening Assay use with other populations counter sales to for Opiates, Oxycodone or with hair specimens nonprofessionals. and Hydrocodone provide other than head. It is an in RapidOne-OXY provides only preliminary analytical vitro diagnostic device only preliminary analytical test results. A more intended exclusively for in- test results. A more specific alternate chemical house professional use only specific alternate chemical method must be used in and not intended for sale to method must be used in order to obtain a anyone. order to obtain a confirmed result. Gas The Quest Diagnostics confirmed result GC/MS is Chromatography – HairCheck-DT (Opiates) the preferred confirmatory Mass Spectrometry provides only preliminary method operating in the selected analytical test results. A ion monitoring (SIM) more specific alternate mode or GC/MS/MS in chemical method must be selected reaction mode used in order to obtain a (SRM) is the preferred confirmed result. Gas method with deuterated Chromatography – internal standards. Other Mass Spectrometry chemical confirmation operating in the selected methods are available. ion monitoring (SIM) Clinical consideration and mode or GC/MS/MS in professional judgment selected reaction mode should be applied to any (SRM) is the preferred drug of abuse test result, method with deuterated particularly when internal standards. Other 3 preliminary positive chemical confirmation results are obtained. methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are obtained. Product Code DJG Same as the proposed Same as the proposed device device Measurand Opiates, Oxycodone and Opiates in hair Oxycodone in urine Hydrocodone in hair Test System International Diagnostics International Diagnostics American Bio Medica Systems Corp Forensic Systems Corp Forensic Corp. Human Drugs of Abuse Human Drugs of Abuse 'RapidOne--OXY' Test One-Step Morphine and IDS One-Step Opiates Oxycodone ELISA for ELISA for Hair Testing Kit Hair Testing Kits Sample Head Hair Same as the proposed Urine matrix device Method of Microplate reader, read at Same as the proposed Lateral flow immunoassay, measurement 450 nm device visually read endpoint Cutoff 300 pg Opiates/mg hair 500 pg Opiates/mg hair 100 ng Oxycodone/mL 300 pg Oxycodone/mg hair urine 300 pg Hydrocodone/mg hair Type of test ELISA Same as the proposed Immunoassay device Extraction Acid-methanol Methanol Not Applicable methods Confirmation GC/MS Same as the proposed Same as the proposed method device device K. Standard/Guidance Document Referenced (if applicable): None were referenced L. Test Principle: 4 Screening Assay: The test consists of two parts; a pre-analytical hair treatment procedure (to convert the solid matrix of hair to a measurable liquid matrix) and the screening assay. The screening assay is an Enzyme-Linked ImmunoSorbent Assay (ELISA). Sample is added to a well of the micro strip plate and enzyme conjugate is added, followed by incubation. During this phase the enzyme-labeled drug conjugate competes with drug in the sample for a limited number of binding sites on the antibody-coated micro wells. The two bind in proportion to their concentrations. A wash solution is applied to remove unbound materials. Enzyme substrate solution containing a chromagen is added. The reaction is stopped with a stop solution and absorbance is read using a plate reader at 450 nm. A background reading is also taken at 630 nm. Color intensity is inversely proportional to the amount of drug presented in the sample. M. Performance Characteristics (if/when applicable): 1. Analytical performance: a. Precision/Reproducibility: Precision studies were performed by taking commercially available materials consisting of morphine in methanol, oxycodone in methanol and hydrocodone in methanol (all with a Certificate of Analysis traceable to NIST) to prepare spiking solutions at the following concentrations; negative, ±75%, ±50%, ±25% and 200% of the cutoff. The concentration of each sample was confirmed by GC/MS. The morphine and oxycodone solutions were then used to spike 11 replicates of negative hair samples. The hydrocodone solution was used to spike 10 replicates of negative hair samples. Intra-assay precision was performed in one run and inter-assay precision was performed over 20 non-consecutive days (10 non-consecutive days for hydrocodone). The results are presented in the tables below: Intra-assay Morphine Cutoff = 300 pg/mg Conc. (pg/mg) % of Cutoff Number Tested Negative Positive 0 Negative 11 11 0 75 -75 11 11 0 150 -50 11 11 0 225 -25 11 11 0 375 125 11 0 11 450 150 11 0 11 525 175 11 0 11 600 200 11 0 11 5 Intra-assay Oxycodone Cutoff = 300 pg/mg Conc. (pg/mg) % of Cutoff Number Tested Negative Positive 0 Negative 11 11 0 75 -75 11 11 0 150 -50 11 11 0 225 -25 11 11 0 375 125 11 0 11 450 150 11 0 11 525 175 11 0 11 600 200 11 0 11 Intra-assay Hydrocodone Cutoff = 300 pg/mg Conc. (pg/mg) % of Cutoff Number Tested Negative Positive 0 Negative 10 10 0 75 -75 10 10 0 150 -50 10 10 0 225 -25 10 9 1 375 125 10 0 10 450 150 10 0 10 525 175 10 0 10 600 200 10 0 10 Inter–assay Morphine Cutoff = 300 pg/mg Conc. (pg/mg) % of Cutoff Number Tested Negative Positive 0 Negative 220 220 0 75 -75 220 220 0 150 -50 220 220 0 225 -25 220 220 0 375 125 220 0 220 450 150 220 0 220 525 175 220 0 220 600 200 220 0 220 Inter–assay Oxycodone Cutoff = 300 pg/mg Conc. (pg/mg) % of Cutoff Number Tested Negative Positive 0 Negative 220 220 0 75 -75 220 220 0 150 -50 220 220 0 225 -25 220 220 0 375 125 220 0 220 450 150 220 0 220 6 525 175 220 0 220 600 200 220 0 220 Inter–assay Hydrocodone Cutoff = 300 pg/mg Conc. (pg/mg) % of Cutoff Number Tested Negative Positive 0 Negative 100 100 0 75 -75 100 100 0 150 -50 100 100 0 225 -25 100 61 39 375 125 100 0 100 450 150 100 0 100 525 175 100 0 100 600 200 100 0 100 The sponsor also performed an intra-assay precision for morphine, oxycodone and hydrocodone using 5 hair specimens for each drug analyte previously found to be positive.
Recommended publications
  • Information to Users

    Information to Users

    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Opioid Receptorsreceptors

    Opioid Receptorsreceptors

    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
  • Opioid Imaging

    Opioid Imaging

    529 NEUROIMAGING CLINICS OF NORTH AMERICA Neuroimag Clin N Am 16 (2006) 529–552 Opioid Imaging Alexander Hammers, PhDa,b,c,*, Anne Lingford-Hughes, PhDd,e - Derivation, release, peptide action, Changes in receptor availability in pain and metabolism and discomfort: between-group - Receptors and ligands comparisons Receptors Direct intrasubject comparisons of periods Species differences with pain and pain-free states Regional and layer-specific subtype - Opioid imaging in epilepsy distributions Focal epilepsies Ligands Idiopathic generalized epilepsy - Positron emission tomography imaging Summary of opioid receptors - Opioid imaging in other specialties Introduction PET imaging Movement disorders Quantification of images Dementia Available ligands and their quantification Cardiology - Opioid receptor imaging in healthy - Opioid imaging in psychiatry: addiction volunteers - Summary - Opioid imaging in pain-related studies - Acknowledgments - References Opioids derive their name from the Greek o´pioy agonists provided evidence for the existence of mul- for poppy sap. Various preparations of the opium tiple receptors [4]. In the early 1980s, there was ev- poppy Papaver somniferum have been used for pain idence for the existence of at least three types of relief for centuries. Structure and stereochemistry opiate receptors: m, k, and d [5,6]. A fourth ‘‘orphan’’ are essential for the analgesic actions of morphine receptor (ORL1 or NOP1) displays a high degree and other opiates, leading to the hypothesis of the of structural homology with conventional opioid existence of specific receptors. Receptors were iden- receptors and was identified through homology tified simultaneously by three laboratories in 1973 with the d receptor [7], but the endogenous ligand, [1–3]. The different pharmacologic activity of orphanin FQ/nociceptin, does not interact directly Dr.
  • Measuring Ligand Efficacy at the Mu- Opioid Receptor Using A

    Measuring Ligand Efficacy at the Mu- Opioid Receptor Using A

    RESEARCH ARTICLE Measuring ligand efficacy at the mu- opioid receptor using a conformational biosensor Kathryn E Livingston1,2, Jacob P Mahoney1,2, Aashish Manglik3, Roger K Sunahara4, John R Traynor1,2* 1Department of Pharmacology, University of Michigan Medical School, Ann Arbor, United States; 2Edward F Domino Research Center, University of Michigan, Ann Arbor, United States; 3Department of Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, San Francisco, United States; 4Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, United States Abstract The intrinsic efficacy of orthosteric ligands acting at G-protein-coupled receptors (GPCRs) reflects their ability to stabilize active receptor states (R*) and is a major determinant of their physiological effects. Here, we present a direct way to quantify the efficacy of ligands by measuring the binding of a R*-specific biosensor to purified receptor employing interferometry. As an example, we use the mu-opioid receptor (m-OR), a prototypic class A GPCR, and its active state sensor, nanobody-39 (Nb39). We demonstrate that ligands vary in their ability to recruit Nb39 to m- OR and describe methadone, loperamide, and PZM21 as ligands that support unique R* conformation(s) of m-OR. We further show that positive allosteric modulators of m-OR promote formation of R* in addition to enhancing promotion by orthosteric agonists. Finally, we demonstrate that the technique can be utilized with heterotrimeric G protein. The method is cell- free, signal transduction-independent and is generally applicable to GPCRs. DOI: https://doi.org/10.7554/eLife.32499.001 *For correspondence: [email protected] Competing interests: The authors declare that no Introduction competing interests exist.
  • Federal Register/Vol. 76, No. 36/Wednesday

    Federal Register/Vol. 76, No. 36/Wednesday

    10068 Federal Register / Vol. 76, No. 36 / Wednesday, February 23, 2011 / Notices Drug Schedule registration to import a basic class of Dated: February 15, 2011. any controlled substance in schedule I Joseph T. Rannazzisi, Diethyltryptamine (7434) .............. I or II are, and will continue to be, Deputy Assistant Administrator, Office of Dimethyltryptamine (7435) ........... I required to demonstrate to the Deputy Diversion Control, Drug Enforcement Psilocybin (7437) .......................... I Assistant Administrator, Office of Administration. Psilocyn (7438) ............................. I [FR Doc. 2011–3948 Filed 2–22–11; 8:45 am] 1-[1-(2- I Diversion Control, Drug Enforcement Thienyl)cyclohexyl]piperidine Administration, that the requirements BILLING CODE 4410–09–P (7470). for such registration pursuant to 21 N-Benzylpiperazine (BZP) (7493) I U.S.C. 958(a); 21 U.S.C. 823(a); and 21 Heroin (9200) ............................... I CFR 1301.34(b), (c), (d), (e), and (f) are DEPARTMENT OF JUSTICE Normorphine (9313) ..................... I satisfied. Etonitazene (9624) ....................... I Drug Enforcement Administration Amphetamine (1100) .................... II Dated: February 15, 2011. Methamphetamine (1105) ............ II Joseph T. Rannazzisi, Manufacturer of Controlled Methylphenidate (1724) ................ II Substances; Notice of Application Deputy Assistant Administrator, Office of Amobarbital (2125) ....................... II Diversion Control, Drug Enforcement Pentobarbital (2270) ..................... II Administration.
  • Salvinorin A, TRK-820 and 3FLB) on ␬ Opioid Receptors in Vitro and Their Antipruritic and Antinociceptive Activities in Vivo

    Salvinorin A, TRK-820 and 3FLB) on ␬ Opioid Receptors in Vitro and Their Antipruritic and Antinociceptive Activities in Vivo

    0022-3565/05/3121-220–230$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 312, No. 1 Copyright © 2005 by The American Society for Pharmacology and Experimental Therapeutics 73668/1186283 JPET 312:220–230, 2005 Printed in U.S.A. Comparison of Pharmacological Activities of Three Distinct ␬ Ligands (Salvinorin A, TRK-820 and 3FLB) on ␬ Opioid Receptors in Vitro and Their Antipruritic and Antinociceptive Activities in Vivo Yulin Wang, Kang Tang, Saadet Inan, Daniel Siebert, Ulrike Holzgrabe, David Y.W. Lee, Peng Huang, Jian-Guo Li, Alan Cowan, and Lee-Yuan Liu-Chen Department of Pharmacology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, Pennsylvania (Y.W., K.T., S.I., P.H., J.-G.L., A.C., L.-Y.L.-C.); The Salvia divinorum Research and Information Center, Malibu, California (D.S.); Institut fur Pharmazie und Lebensmittelchemie, Universitat Wurzburg, Germany (U.H.); and McLean Hospital, Harvard Medical School, Belmont, Massachusetts (D.Y.W.L.) Received July 3, 2004; accepted September 21, 2004 ABSTRACT Salvinorin A, TRK-820 (17-cyclopropylmethyl-3,14␤-dihydroxy-4,5␣- agonist on MOR and DOR, whereas salvinorin A and 3FLB epoxy-6␤-[N-methyl-trans-3-(3-furyl) acrylamido]morphinan hydro- showed no activities on these receptors. Salvinorin A, TRK-820, chloride), and 3FLB (diethyl 2,4-di-[3-fluorophenyl]-3,7-dimethyl-3,7- and 3FLB caused internalization of the human KOR in a dose- diazabicyclo[3.3.1]nonane-9-one-1,5-dicarboxylate) are structurally dependent manner. Interestingly, although salvinorin A and distinctly different from U50,488H [(trans)-3,4-dichloro-N-methyl-N- U50,488H had similar potencies in stimulating [35S]GTP␥S bind- [2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide methanesulfonate], ing, salvinorin A was about 40-fold less potent than U50,488H in the prototypic selective ␬ agonist.
  • Drugs of Abuseon September Archived 13-10048 No

    Drugs of Abuseon September Archived 13-10048 No

    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
  • Chapter 329 [New] Uniform Controlled Substances Act

    Chapter 329 [New] Uniform Controlled Substances Act

    CHAPTER 329 [NEW] UNIFORM CONTROLLED SUBSTANCES ACT Part I. General Provisions Section 329-1 Definitions 329-2 Hawaii advisory commission on drug abuse and controlled substances; number; appointment 329-3 Annual report 329-4 Duties of the commission Part II. Standards and Schedules 329-11 Authority to schedule controlled substances 329-12 Nomenclature 329-13 Schedule I tests 329-14 Schedule I 329-15 Schedule II tests 329-16 Schedule II 329-17 Schedule III Tests 329-18 Schedule III 329-19 Schedule IV tests 329-20 Schedule IV 329-21 Schedule V tests 329-22 Schedule V 329-23 Republishing and distribution of schedules Part III. Regulation of Manufacture, Distribution, Prescription, and Dispensing of Controlled Substances 329-31 Rules 329-31.5 Clinics 329-32 Registration requirements 329-33 Registration 329-34 Revocation and suspension of registration 329-35 Order to show cause 329-36 Records of registrants 329-37 Filing requirements 329-38 Prescriptions 329-39 Labels 329-40 Methadone treatment programs Part IV. Offenses and Penalties 329-41 Prohibited acts B-penalties 329-42 Prohibited acts C-penalties 329-43 Penalties under other laws 329-43.5 Prohibited acts related to drug paraphernalia Amended 0612 1 329-44 Notice of conviction to be sent to licensing board, department of commerce and consumer affairs 329-45 Repealed 329-46 Prohibited acts related to visits to more than one practitioner to obtain controlled substance prescriptions 329-49 Administrative penalties 329-50 Injunctive relief Part V. Enforcement and Administrative Provisions 329-51 Powers of enforcement personnel 329-52 Administrative inspections 329-53 Injunctions 329-54 Cooperative arrangements and confidentiality 329-55 Forfeitures 329-56 Burden of proof; liabilities 329-57 Judicial review 329-58 Education and research 329-59 Controlled substance registration revolving fund; established Part VI.
  • Pentazocine Elisa Kit Instructions Product #103119 & 103116

    Pentazocine Elisa Kit Instructions Product #103119 & 103116

    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology PENTAZOCINE ELISA KIT INSTRUCTIONS PRODUCT #103119 & 103116 INTENDED USE: For the determination of trace quantities of Pentazocine and/or other metabolites in human urine, blood, oral fluid. DESCRIPTION Neogen Corporation’s Pentazocine ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug-enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the diluted drug-enzyme conjugate is added and the mixture is incubated at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed 3 times to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB). After a 30 minute substrate incubation, the reaction is halted with the addition of Red Stop Solution.
  • NIDA Drug Supply Program Catalog, 25Th Edition

    NIDA Drug Supply Program Catalog, 25Th Edition

    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
  • Drug and Medication Classification Schedule

    Drug and Medication Classification Schedule

    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine